Results 291 to 300 of about 4,357,163 (359)

The PI3Kδ inhibitor roginolisib (IOA‐244) preserves T‐cell function and activity

open access: yesMolecular Oncology, EarlyView.
Identification of novel PI3K inhibitors with limited immune‐related adverse effects is highly sought after. We found that roginolisib and idelalisib inhibit chronic lymphocytic leukemia (CLL) cells and Treg suppressive functions to similar extents, but roginolisib affects cytotoxic T‐cell function and promotion of pro‐inflammatory T helper subsets to a
Elise Solli   +7 more
wiley   +1 more source

Multidimensional Assessment of Neurological Adverse Reactions Related to PD-1 Inhibitors: A Real-World Pharmacovigilance Study. [PDF]

open access: yesCNS Neurosci Ther
Hu X   +12 more
europepmc   +1 more source

Enhancing the efficacy of VEGF inhibitors by co-inhibition of HIF in the treatment of glioblastoma. [PDF]

open access: yesApoptosis
Harbi E   +11 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy